This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Vaccinia Virus B18R Protein, His Tag
catalog :
B1R-H52H6
quantity :
50 ug, 500 ug
price :
450 USD, 1900 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
B1R-H52H6
product name :
Vaccinia Virus B18R Protein, His Tag
quantity :
50 ug, 500 ug
price :
450 USD, 1900 USD
quantity & price :
$450/50ug,$1900/500ug
target :
B18R
host species :
Vaccinia Virus
By Tag :
His Tag
Research :
For Research Use Only
Source :
Vaccinia Virus B18R, His Tag, His 20 - Glu 351 (Accession # P25213), was produced in human 293 cells (HEK293) at ACROBiosystems.
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Vaccinia Virus B18R, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
B18R is a type I interferon (IFN)-binding protein and it is encoded by the B18R open reading frame in the WR (Western Reserve) strain of vaccinia virus, which contains two Ig-like C2-type domains and one Ig-like V-type domain. B18R exists in a soluble and a membrane-bound form. As a type I IFN receptor, B18R counteracts the antiviral effects of host IFN-alpha/beta. Also, B18R acts as a soluble IFN-alpha receptor and thus inhibits the interaction between host IFN-alpha and its receptor.
References :
(1) Alcami A., et al., 2000, J. Virol. 74:11230-11239.
(2) Waibler Z., et al., 2009, J. Virol. 83:1563-1571.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments